Current HIV therapeutics target biological features that evolution can modify, explaining why 30+ antiretroviral drugs achieve suppression but not cure. We propose a physics-based framework that exploits high-barrier thermodynamic constraints—regions where mutations impose severe fitness costs on the virus. Our approach comprises three integrated components: (1) The Entropic Vise, targeting the gp41 HR1 domain (HXB2 residues 546-556) which exhibits near-zero Shannon entropy across 500,000+ sequences, indicating strong purifying selection; (2) Thermodynamically Constrained Generative Models that predict future variants; and (3) Sentinel Cells engineered with humanized reporters (ΔNGFR) for real-time latency detection. While clinical data from Enfuvirtide demonstrate that resistance mutations can emerge under selective pressure, these escape mutants exhibit significant fitness costs. This framework proposes high-barrier targeting as a testable hypothesis for complementary therapeutic strategies.
Rhine Lesther Tague (Sun,) studied this question.